AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
AYTU BIOPHARMA, INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026
$1.96−0.08 (-3.92%)
Close on Oct 19, 2026
- Market cap
- $37.82M
- P/E (TTM)
- –
- Dividend yield
- –
AYTU BIOPHARMA, INC revenue by segment
By business segment
| Revenue | TTM Q4 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RX Segment [Member] | $57.57M | – | $66.38M | – | – | – | – | – | – | – | – | – | 100.0% | -13.3% |
| Consumer Health [Member] | – | – | – | – | – | – | $15.82M | $19.86M | $24.82M | $28.88M | $33.60M | $34.90M | – | – |
| Rx Segment [Member] | – | $63.70M | $66.38M | $65.84M | $61.41M | $63.94M | $65.18M | $73.90M | $73.68M | $72.96M | $73.80M | – | – | – |
| Rx | – | – | – | – | – | – | – | – | – | $72.96M | $73.80M | $69.22M | – | – |
| Operating income | TTM Q4 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Consumer Health [Member] | – | – | – | – | – | – | -$3.66M | -$8.34M | -$8.91M | -$9.53M | -$9.71M | – | – |
| Rx Segment [Member] | – | – | – | – | – | – | -$1.59M | – | – | – | -$7.36M | – | – |
By product or service
By region
From the segment and revenue-disaggregation notes of Aytu Biopharma's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.